R&D expenses of Innovent Biologics 2019-2022
In 2022, the Chinese pharmaceutical firm Innovent Biologics Inc. spent more than 2.8 billion yuan on research and development projects, representing a growth of more than 500 million yuan from the previous year. The core products of Innovent Biologics include anti-tumor medicines and drugs treating metabolic disorders and autoimmune diseases.